drugset
Drugs / CYD Dengue Vaccine
last change Jan 2023 re-read 9 days ago

CYD Dengue Vaccine

also known as CYD-TDV · Dengvaxia · Sanofi Pasteur's CYD Dengue Vaccine

Vaccine

Developed for
Dengue hemorrhagic fever
Investigated by
Sanofi Pasteur, a Sanofi Company · Sanofi · United States Department of Defense

Trials 12

today NCT02741128 · Ph 2 NCT02992418 · Ph 3 NCT02993757 · Ph 3 NCT02979535 · Ph 3 NCT02628444 · Ph 2 NCT02623725 · Ph 2 NCT01943825 · Ph 2 NCT01411241 · Ph 3 NCT01064141 · Ph 2 NCT00880893 · Ph 2 NCT00875524 · Ph 2 NCT00842530 · Ph 2
2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 28 trials · 1 met primary · 1 missed
Phase 2 NCT02741128 Nov 2019 → Jan 2023 Dengue hemorrhagic fever, HIV infectious disease Sanofi Pasteur, a Sanofi Company Completed No outcome recorded
Phase 2 NCT02628444 May 2016 → Apr 2020 Dengue hemorrhagic fever Sanofi Pasteur, a Sanofi Company Completed Mixed
Phase 2 NCT02623725 Apr → Nov 2016 Dengue hemorrhagic fever Sanofi Pasteur, a Sanofi Company Completed Met primary
Phase 2 NCT01943825 Nov 2013 → Nov 2015 Dengue hemorrhagic fever Sanofi Pasteur, a Sanofi Company Completed No outcome recorded
Phase 2 NCT01064141 Jan 2010 → Sep 2012 Dengue hemorrhagic fever Sanofi Completed No outcome recorded
Phase 2 NCT00880893 Apr 2009 → Oct 2014 Dengue hemorrhagic fever Sanofi Pasteur, a Sanofi Company Completed No outcome recorded
Phase 2 NCT00875524 Mar 2009 → Aug 2014 Dengue hemorrhagic fever Sanofi Pasteur, a Sanofi Company Completed No outcome recorded
Phase 2 NCT00842530 Feb 2009 → Sep 2013 Dengue hemorrhagic fever Sanofi Pasteur, a Sanofi Company Completed Missed primary
Phase 34 trials · 1 met primary
Phase 3 NCT02992418 Dec 2016 → Dec 2019 Dengue hemorrhagic fever Sanofi Pasteur, a Sanofi Company Terminated Met primary
Phase 3 NCT02993757 Dec 2016 → May 2019 Dengue hemorrhagic fever, human papilloma virus infection Sanofi Pasteur, a Sanofi Company Completed No outcome recorded
Phase 3 NCT02979535 Nov 2016 → Mar 2019 Dengue hemorrhagic fever, human papilloma virus infection Sanofi Pasteur, a Sanofi Company Completed No outcome recorded
Phase 3 NCT01411241 Jul 2011 → Feb 2014 Dengue hemorrhagic fever Sanofi Pasteur, a Sanofi Company Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 18 sources stand behind the page.

FieldValueCited text
Known as CYD Dengue Vaccine “The aim of the study was to investigate the immunogenicity and safety of CYD dengue vaccine and Tetanus Toxoid (T), Reduced Diphtheria Toxoid (D) and Acellular Pertussis...” NCT02992418 ↗
13

“The purpose of this study is to investigate the potential for co-administration of the first dose of CYD Dengue vaccine with childhood vaccination.” NCT01064141 ↗

“CYD Dengue Vaccine” NCT01064141 ↗

“CYD Dengue Vaccine” NCT01411241 ↗

NCT02979535 ↗

NCT02741128 ↗

NCT02628444 ↗

NCT00842530 ↗

NCT01943825 ↗

NCT00875524 ↗

NCT00880893 ↗

Show 3 more sources
Known as CYD-TDV “BACKGROUND: Incorporating dengue vaccination into existing childhood vaccination programs could increase vaccine coverage. This study assessed the safety and immunogenicity of...” PMID 34117198 ↗ Sep 2021
5

“We assessed the immunogenicity and safety of a quadrivalent human papillomavirus (HPV) vaccine administered concomitantly or sequentially with a tetravalent dengue vaccine...” PMID 34250977 ↗ Aug 2021

“Three doses of the licensed tetravalent dengue vaccine CYD-TDV (Dengvaxia, Sanofi Pasteur, Lyon France) are immunogenic and effective against symptomatic dengue” PMID 33212067 ↗ Nov 2020

“The tetravalent dengue vaccine (CYD-TDV, Dengvaxia, Sanofi Pasteur) demonstrated efficacy in 2 previous phase III trials conducted in endemic countries.” PMID 30986790 ↗ May 2019

“The recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TDV) is recommended for dengue seropositive individuals” PMID 33992441 ↗ May 2021

“CYD-TDV, a live, attenuated, tetravalent dengue vaccine” PMID 33822015 ↗ Sep 2021
Known as Dengvaxia “Three doses of the licensed tetravalent dengue vaccine CYD-TDV (Dengvaxia, Sanofi Pasteur, Lyon France) are immunogenic and effective against symptomatic dengue” PMID 33212067 ↗ Nov 2020
1

“The tetravalent dengue vaccine (CYD-TDV, Dengvaxia, Sanofi Pasteur) demonstrated efficacy in 2 previous phase III trials conducted in endemic countries.” PMID 30986790 ↗ May 2019
Known as Sanofi Pasteur's CYD Dengue Vaccine “Sanofi Pasteur's CYD Dengue Vaccine” NCT00880893 ↗
Modality Vaccine “CYD-TDV, a live, attenuated, tetravalent dengue vaccine” PMID 33822015 ↗ Sep 2021
Route Subcutaneous “0.5 mL, Subcutaneous” NCT00842530 ↗